For example, first- and second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) erlotinib (Tarceva), gefitinib (Iressa), afatinib, and dacomitinib have been used in clinic for the treatment of different cancers, offering new therapeutic approaches and an effective long-term cancer therapy (Slamon et al., 2001; Perez et al., 2014). This evidence concerns the gene EGFR and cancer.